Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models.

Animals Mice Polymers / chemistry Drug Carriers / chemistry Nanomedicine Cell Line, Tumor Doxorubicin / pharmacokinetics Disease Models, Animal
Biodistribution Cancer Drug delivery HPMA Polymeric carriers Positron emission tomography

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
01 2023
Historique:
received: 31 10 2022
revised: 25 11 2022
accepted: 30 11 2022
pmc-release: 01 01 2024
pubmed: 6 12 2022
medline: 3 2 2023
entrez: 5 12 2022
Statut: ppublish

Résumé

Nanomedicines are considered next generation therapeutics with advanced therapeutic properties and reduced side effects. Herein, we introduce tailored linear and star-like water-soluble nanosystems as stimuli-sensitive nanomedicines for the treatment of solid tumors or hematological malignancies. The polymer carrier and drug pharmacokinetics were independently evaluated to elucidate the relationship between the nanosystem structure and its distribution in the body. Positron emission tomography and optical imaging demonstrated enhanced tumor accumulation of the polymer carriers in 4T1-bearing mice with increased tumor-to-blood and tumor-to-muscle ratios. Additionally, there was a significant accumulation of doxorubicin bound to various polymer carriers in EL4 tumors, as well as excellent in vivo therapeutic activity in EL4 lymphoma and moderate efficacy in 4T1 breast carcinoma. The linear nanomedicine showed at least comparable pharmacologic properties to the star-like nanomedicines regarding doxorubicin transport. Therefore, if multiple parameters are considered such as its optimized structure and simple and reproducible synthesis, this polymer carrier system is the most promising for further preclinical and clinical investigations.

Identifiants

DOI: 10.1016/j.jconrel.2022.11.060 PMID: 36470330 PMC: PMC9892306
pubmed: 36470330
pii: S0168-3659(22)00814-8
doi: 10.1016/j.jconrel.2022.11.060
pmc: PMC9892306
mid: NIHMS1857034
pii:
doi:

Substances chimiques

Polymers 0
Drug Carriers 0
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

549-562

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Weibo Cai is a scientific advisor, stockholder, and grantee of Focus-X Therapeutics, Inc. All other authors declare no conflict of interest.

Références

Adv Drug Deliv Rev. 2010 Feb 17;62(2):184-91
pubmed: 19914318
Biomacromolecules. 2018 Oct 8;19(10):4003-4013
pubmed: 30180562
Drug Deliv Transl Res. 2020 Jun;10(3):721-725
pubmed: 32166632
Pharmaceutics. 2020 Dec 20;12(12):
pubmed: 33419291
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Chem Rev. 2009 Nov;109(11):5402-36
pubmed: 19764725
Mol Pharm. 2014 May 5;11(5):1715-20
pubmed: 24750072
Nanomedicine (Lond). 2020 Aug;15(23):2311-2324
pubmed: 32969312
Exp Mol Pathol. 2007 Feb;82(1):12-24
pubmed: 16919266
J Control Release. 2005 Dec 10;110(1):119-29
pubmed: 16269198
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Cancer Immunol Immunother. 2007 Jan;56(1):35-47
pubmed: 16636810
Biomaterials. 2020 Mar;235:119728
pubmed: 32044514
J Drug Target. 2011 Dec;19(10):874-89
pubmed: 21978286
Adv Drug Deliv Rev. 2020;156:40-64
pubmed: 32735811
Chem Rev. 2016 Jun 22;116(12):6743-836
pubmed: 27299693
Nanoscale. 2017 Aug 3;9(30):10906-10918
pubmed: 28731080
BMC Cancer. 2018 May 22;18(1):582
pubmed: 29788918
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1117-20
pubmed: 19682516
Chem Rev. 2016 May 11;116(9):5338-431
pubmed: 27109701
Oncol Rep. 2015 Oct;34(4):1953-60
pubmed: 26238192
Adv Mater. 2022 Feb;34(8):e2108049
pubmed: 34875724
Adv Drug Deliv Rev. 2020;157:142-160
pubmed: 32553783
Acc Chem Res. 2019 Sep 17;52(9):2445-2461
pubmed: 31424909
J Control Release. 2016 Feb 10;223:1-10
pubmed: 26708020
Mol Pharm. 2017 May 1;14(5):1384-1394
pubmed: 28094954
Physiol Res. 2018 Oct 30;67(Suppl 2):S293-S303
pubmed: 30379551
J Control Release. 2012 Dec 28;164(3):346-54
pubmed: 22759979
Physiol Res. 2016 Oct 20;65(Suppl 2):S179-S190
pubmed: 27762584
Nat Rev Drug Discov. 2003 May;2(5):347-60
pubmed: 12750738

Auteurs

Libor Kostka (L)

Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.

Lenka Kotrchová (L)

Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.

Eva Randárová (E)

Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.

Carolina A Ferreira (CA)

Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States.

Iva Malátová (I)

Institute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic.

Hye Jin Lee (HJ)

Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, United States.

Aeli P Olson (AP)

Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States.

Jonathan W Engle (JW)

Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States.

Marek Kovář (M)

Institute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic.

Weibo Cai (W)

Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, United States; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States.

Milada Šírová (M)

Institute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic.

Tomáš Etrych (T)

Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic. Electronic address: etrych@imc.cas.cz.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Miniaturisation › Nanotechnologie › Nanomédecine › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Anthracyclines › Daunorubicine › Doxorubicine › Evaluation of linear versus star-like polymer...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Evaluation of linear versus star-like polymer...